

OPEN

Phenotypic characterisation of regulatory T cells in dogs reveals signature transcripts conserved in humans and mice

Ying Wu^{1,5}, Yu-Mei Chang¹, Anneliese J. Stell¹, Simon L. Priestnall¹, Eshita Sharma², Michelle R. Goulart^{1,6}, John Gribben³, Dong Xia¹ & Oliver A. Garden^{1,4}

Regulatory T cells (Tregs) are a double-edged regulator of the immune system. Aberrations of Tregs correlate with pathogenesis of inflammatory, autoimmune and neoplastic disorders. Phenotypically and functionally distinct subsets of Tregs have been identified in humans and mice on the basis of their extensive portfolios of monoclonal antibodies (mAb) against Treg surface antigens. As an important veterinary species, dogs are increasingly recognised as an excellent model for many human diseases. However, insightful study of canine Tregs has been restrained by the limited availability of mAb. We therefore set out to characterise CD4⁺CD25^{high} T cells isolated *ex vivo* from healthy dogs and showed that they possess a regulatory phenotype, function, and transcriptomic signature that resembles those of human and murine Tregs. By launching a cross-species comparison, we unveiled a conserved transcriptomic signature of Tregs and identified that transcript *hip1* may have implications in Treg function.

Regulatory T cells (Tregs) are dominant regulators of immune responses against self, pathogenic and commensal antigens in the periphery¹. As key players in the maintenance of immune health, aberrations of Tregs have pathogenic implications in a number of inflammatory, autoimmune and neoplastic diseases, making them a compelling biomarker and immunotherapeutic target^{2–7}. Tregs are heterogeneous in the periphery^{8,9}. Despite the discovery of various Treg subtypes such as type 1 regulatory T (Tr1)^{10,11}, CD8⁺^{12,13}, CD4⁺CD25[–]LAG3⁺^{14,15}, $\gamma\delta$ TCR⁺^{16,17} and invariant natural killer T (iNKT)^{18,19} regulatory cells, CD4⁺FoxP3⁺ Tregs remain as the principal target of investigation in humans and mice^{20,21}. CD4⁺CD25⁺FoxP3⁺ T cells in mice are suppressive^{20,22}, whereas accumulating evidence suggests that CD4⁺FoxP3⁺ T cells in humans are heterogeneous in phenotype and function^{23–25}. In addition to the extensive portfolio of surface markers for human Tregs, including CD25, CD127, CD45RA, ICOS and HLA-DR, sialyl lewis x (CD15s) identifies terminally differentiated effector Tregs²⁶.

Although murine models for a number of pathobiological and immunotherapeutic studies are firmly established, large animal models are increasingly gaining traction. Of these, the dog recapitulates human autoimmune and neoplastic diseases remarkably well. Such diseases are spontaneous in canine patients, which have a competent immune system, and clinical presentations, treatment modalities and living environments shared with their human counterparts^{27–29}. However, in-depth study of canine Tregs has been hampered by the limited availability of monoclonal antibodies (mAb) against surface antigens. Apart from the cross-reactive clones validated for canine intracellular FoxP3 (clone FJK-16s)^{30,31} and Helios (clone 226 F)³¹, anti-CD25 (clone P4A10) is the only known mAb labelling the extracellular surface of canine Tregs³². CD4⁺CD25^{+/high} T cells are enriched for suppressive FoxP3⁺ T cells in humans and mice^{33–35}. Our previous work has shown that canine CD4⁺CD25^{high} T cells induced *in vitro* are regulatory³¹, but studies examining these cells *ex vivo* are limited in number and scope^{36–38}. We therefore set out to characterise canine CD4⁺CD25^{high} T cells isolated *ex vivo*, hypothesising that they possess

¹Royal Veterinary College, London, UK. ²Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.

³Barts Cancer Institute, Queen Mary University of London, London, UK. ⁴School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA. ⁵Present address: School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA. ⁶Present address: Barts Cancer Institute, Queen Mary University of London, London, UK. Dong Xia and Oliver A. Garden jointly supervised this work. Correspondence and requests for materials should be addressed to O.A.G. (email: ogarden@upenn.edu)

regulatory phenotype and function. Furthermore, we investigated the transcriptomic phenotype of Tregs in dogs and compared it with those of humans and mice on the basis of published transcriptomic data, revealing a broadly conserved Treg signature across these species and consensus transcripts encoding molecules not hitherto associated with Tregs.

Materials and Methods

Sample collection. This study was approved by the Clinical Research Ethical Review Board (URN 2016 1592) of the Royal Veterinary College (RVC) in the United Kingdom. Eleven healthy dogs, defined by the absence of clinical signs and a normal physical examination undertaken by a veterinarian or veterinary nurse, were recruited at the RVC. Peripheral blood samples were collected from the jugular or lateral saphenous vein in sterile fashion by a veterinarian or veterinary nurse under the Animals (Scientific Procedures) Act 1986, following informed written consent by the owners of the dogs.

Isolation of peripheral blood mononuclear cells. Mononuclear cells were isolated from the peripheral blood by density gradient centrifugation, using Histopaque[®]-1077 (Sigma-Aldrich, Dorset, UK). Blood was diluted by an equal volume of phosphate-buffered saline (PBS; Sigma-Aldrich) with 2% v/v fetal bovine serum (FBS; Thermo Fisher Scientific, Waltham, MA, USA). The diluted blood was then layered onto an equal volume of Histopaque, before centrifugation at 400 g for 30 minutes at room temperature with minimal acceleration and braking. The purified peripheral blood mononuclear cells (PBMCs) were washed twice in PBS with 10% v/v FBS by centrifuging at 600 g for five minutes at 4 °C. After washing, cells were re-suspended in PBS with 10% v/v FBS, and counted using a haemocytometer before flow cytometric analysis. Dead cells were excluded by trypan blue staining.

Flow cytometry. Freshly isolated PBMCs were analysed by flow cytometry using mAb against canine-specific or cross-reactive antigens (all from Thermo Fisher Scientific). Extracellular labelling was performed by incubating PBMCs for 30 minutes at 4 °C with a mixture of FITC-conjugated anti-dog CD45 (clone YKIX716.13), PerCP-eFluor[®] 710-conjugated anti-dog CD5 (clone YKIX322.3), PE-Cy7-conjugated anti-dog CD4 (clone YKIX302.9), eFluor[®] 450-conjugated anti-dog CD8 (clone YCATE55.9) and PE-conjugated anti-dog CD25 (clone P4A10). After washing twice with PBS, cells were incubated in eBioscience[™] FoxP3/transcription factor fixation/permeabilisation buffer (Thermo Fisher Scientific) according to the manufacturer's instructions, then labelled with APC-conjugated anti-mouse/rat FoxP3 (clone FJK-16s) for 30 minutes at 4 °C. After washing with 1x permeabilisation buffer, cells were re-suspended in 200 µL PBS before being acquired on a FACSCanto II flow cytometer (Becton-Dickinson (BD); Franklin Lakes, NJ, USA). Flow cytometric data were analysed using FlowJo[®] software, version 7.6 (Tree Star, Ashland, OR, USA). Positive events were gated according to corresponding isotype or fluorescence minus one (FMO) controls.

Fluorescence-activated cell sorting. Fluorescence-activated cell sorting (FACS[™]) was used to sort PBMCs into subpopulations for subsequent experiments. Freshly isolated PBMCs were labelled by a mixture of PerCP-eFluor[®] 710-conjugated anti-dog CD5 (clone YKIX322.3), PE-Cy7-conjugated anti-dog CD4 (clone YKIX302.9), PE-conjugated anti-dog CD25 (clone P4A10) and Alexa Fluor[®] 700-conjugated anti-mouse CD11b for 30 minutes at 4 °C. After washing twice with PBS, cells were stained with 4',6-diamidino-2-phenylindole (DAPI; BioLegend, San Diego, CA, USA) at room temperature for 10 minutes prior to sorting on BD FACSAria[™] II. CD4⁺CD25^{high} and CD4⁺CD25⁻ T cells were isolated from CD5⁺CD11b⁻ cells, and autologous antigen-presenting cells (APCs) were identified as CD5⁻CD11b⁺. For functional assays, CD4⁺CD25^{high} T cells were defined as the 5% of CD4⁺ T cells showing the highest CD25 expression, whereas CD4⁺CD25⁻ T cells were defined as the 20% of CD4⁺ T cells showing the lowest CD25 expression. For transcriptomic assays, CD4⁺CD25^{high} T cells were defined as the 1% of CD4⁺ T cells showing the highest CD25 expression, whereas CD4⁺CD25⁻ T cells were defined as before.

In vitro suppression assay. CD4⁺CD25^{high} and CD4⁺CD25⁻ T cells sorted from the peripheral blood of healthy dogs were immediately re-suspended in complete culture medium (RPMI-1640 complemented with 10% v/v FBS, 10 mM HEPES, 100 µg/mL streptomycin, 100 U/mL penicillin and 0.5 mM β-mercaptoethanol; all reagents from Sigma-Aldrich). The responder T (Tresp) cell population (CD4⁺CD25⁻) was stained with CellTrace[™] violet proliferation dye according to the manufacturer's instructions (Thermo Fisher Scientific), and seeded into a 96-well plate at a density of 1–5 × 10⁴ cells per well. The suppressor cell population (CD4⁺CD25^{high}) was co-cultured with Tresp cells at a ratio (Treg:Tresp) of 1:1 and/or 1:2. A population of autologous CD5⁻CD11b⁺ monocytes at a proportion of 1/5 of that of Tresp cells were also seeded into each well, as APCs. The mixed cell culture contained a total volume of 200 µL with 2.5 µg/mL concanavalin A (ConA) (Sigma-Aldrich) and was incubated for 96 hours at 37 °C, with 5% CO₂. Three control groups were set up in the same fashion, including un-stimulated Tresp alone, stimulated Tresp alone and CD4⁺CD25⁻ co-cultured with Tresp.

RNA extraction. CD4⁺CD25^{high} and CD4⁺CD25⁻ T cells sorted from the peripheral blood of five healthy dogs were immediately re-suspended in RNA Bee (AMS Biotechnology, Abingdon, UK) at a density of 2 × 10⁶ cells/mL. Two hundred microlitres of chloroform (Sigma-Aldrich) per millilitre of RNA Bee suspension were added, before thorough admixture, transfer to a 2 mL MaXtract High Density tube (QIAGEN, Hilden, Germany), and incubation on ice for three minutes. The tube was then centrifuged at 12,000 g for 15 minutes at 4 °C. After centrifugation, the upper aqueous layer was carefully transferred to a 1.5 mL DNase/RNase-free Eppendorf Tube[®] (Eppendorf, Stevenage, UK), before being mixed completely with an equal volume of 100% ethanol (Sigma-Aldrich). The mixture was then transferred into a Zymo-Spin[™] IC column on top of a collection tube and centrifuged according to the manufacturer's instructions (Direct-zol[™] RNA MicroPrep Kit, Zymo Research,

Irvine, CA, USA). All samples were treated with DNase I during extraction; the final product was eluted in 6–10 µL of DNase/RNase-free water.

Library construction and sequencing. SMARTer® Universal Low Input RNA Kit (Clontech, California, USA) was used to construct the complementary (c) DNA library at the Oxford Genomics Centre, University of Oxford (Oxford, UK). RNA was converted to cDNA using Oligo (dT) primers and adapters, followed by PCR amplification. The cDNA library was then sheared into short fragments using a Covaris S220 Focused-Ultrasonicator (Thermo Fisher Scientific) for subsequent random shotgun Illumina sequencing. The 75-bp, paired-end sequencing was performed on the prepared DNA libraries, using the HiSeq. 4000 System (Illumina, San Diego, CA, USA) at the Oxford Genomics Centre. Samples were loaded onto the clustered sequencing Flow Cell, which was then primed with sequencing by synthesis (SBS) reagents and hybridised by Read 1 and Read 2 primers. The run was recorded by HCS 3.4.0 (Illumina).

Read processing and expression quantification. Sequencing reads were trimmed using Skewer (version 0.1.125) to remove the adapter and anchor sequences added during library construction and sequencing. Trimmed transcript reads were mapped to the canine genome, CanFam3.1 (Ensembl Genes, release 91), using HISAT2 (version 2.0.0-beta). The uniquely mapped read pairs were quantified using featureCounts (version 1.5.0), and annotated using the same canine genomic data. Mapping metrics were generated using Picard Tools (version 1.92). The metrics and variants for assessing read distribution, biotype distribution and mapped transcripts were generated using R packages (version 3.4.2) with in-house scripts. Read counts were all converted to transcripts per million (TPM) to normalise sequencing depth and gene lengths.

Differential expression analysis. Transcripts differentially expressed between canine CD4⁺CD25^{high} and CD4⁺CD25⁻ T cells were identified using Bioconductor package edgeR (Bioconductor version 3.6), with fold change (FC) values and statistical significance, the latter of which was represented by false discovery rate (FDR). R version 3.4.2 was used to conduct principal component analysis (PCA) and volcano plots.

Ingenuity pathway analysis. Differentially expressed transcripts (FDR < 0.05) with FC and FDR values were input into the software Ingenuity Pathway Analysis (IPA; Ingenuity Systems Inc., Redwood City, CA, USA) to identify biological pathways affected by the altered expression of these transcripts ($|Z|$ score ≥ 2).

Reverse transcription and quantitative PCR. Purified total RNA was converted to cDNA by performing reverse transcription (RT), using the Precision nanoScript™ 2 Reverse Transcription Kit (Primerdesign, Southampton, UK). One reaction of 20 µL volume in total contained RNA template (up to 2 µg), combined Oligo (dT) and random nonamer primers, nanoScript™ 2 Buffer, dNTP mix, nanoScript™ 2 enzyme and RNase/DNase free water. The reaction included an annealing step of 65 °C for five minutes, then immediate cooling on ice, followed by an extension step at room temperature for five minutes and 42 °C for 20 minutes, then 75 °C for 10 minutes. The abundance of transcripts of interest was then measured by quantitative (q) PCR, using cDNA as reaction template, according to the manufacturer's instructions. Primers specific to each transcript were all from the Taqman® Gene Expression Assays (GEAs) (Thermo Fisher Scientific), targeting *fam129a* (Cf02724989_m1), *lmna* (Cf02678125_g1), *cadm1* (Cf02645230_m1), *anxa2* (Cf02734571_gH), *ctsz* (Cf02661948_m1), *actn4* (Cf02689744_g1), *csf1* (Cf01094425_m1), *hip1* (Cf02698307_m1), *galn* (Cf02648153_m1), *pou2f2* (Cf00922171_g1), *frmd4b* (Cf02646908_m1), *il2ra* (Cf02623133_m1), *foxp3* (Cf02741700_m1) and *ikzf2* (Cf00915981_m1). Two reference transcripts, *ubc* encoding CG11624-PA, isoform A and *sdha* encoding succinate dehydrogenase flavoprotein subunit, were selected following validation by means of the Primerdesign Dog geNorm™ Kit. The relative expression of the target transcript was calculated using Pfaffl's model³⁹ as below:

$$Relative\ expression = \frac{(E_{TAR})^{\Delta C_{qTAR}(Control-Sample)}}{(E_{REF})^{\Delta C_{qREF}(Control-Sample)}}$$

E represents E value; TAR, target transcript; REF, reference transcript; Control, CD4⁺CD25⁻ cells; Sample, CD4⁺CD25^{high} cells. The relative expression ratio calculated by this equation indicated the FC of the target transcript abundance in the sample population when compared to that of the control population.

Interspecies comparisons. To compare the transcriptomic profiles of canine CD4⁺CD25^{high} T cells across species with those of human and murine Tregs, published resources were used. The selected human and murine studies^{22,40} used different analytical methods from those in this study, but were the most comprehensive in the literature and conducted on freshly isolated Tregs in comparison to CD4⁺CD25⁻ T cells. Raw transcriptomic data of the published human and murine studies were analysed following the same pipeline as for canine CD4⁺CD25^{high} T cells, with respective genomic information. The data were processed using the web-based bioinformatics platform *Galaxy*⁴¹. Similarity scores were calculated using R OrderedList⁴² (version 1.48.0), to determine the number of shared transcripts between two species in the first n consensus transcripts, which were ordered by differential expression FC values. A similarity score was yielded, in which transcripts received higher weight the closer they were to the top or bottom end of the ordered list. Similarity scores for n = 100, 150, 200, 300, 400, 500 and 750 transcripts were reported, respectively. Statistical significance was assessed for each of the similarity scores, by comparing with a null distribution generated by randomly scrambling the order of the transcripts.

Statistical analysis. Summary data are shown as mean \pm standard error of the mean (SEM). Statistical analysis was performed using GraphPad Prism version 7 (GraphPad Software, La Jolla, CA, USA).




Figure 1. CD4⁺CD25^{high} T cells isolated *ex vivo* are enriched for FoxP3. **(a)** Representative flow cytometric plots showing that proportional expression of FoxP3 increased with increasing CD25 expression by CD4⁺ T cells from the highest 5% to the highest 0.5% of one healthy dog (all CD4⁺CD25⁺ T cells in this figure were analysed as CD45⁺CD5⁺CD8⁻CD4⁺CD25⁺, following a cascaded gating strategy). **(b)** Scatter dot plot summarising the increasing proportional expression of FoxP3 (mean \pm SEM) among CD4⁺ T cells of 11 healthy dogs, with increasing CD25 expression from the highest 5% to the highest 0.2%. **(c)** Summary scatter dot plot comparing the higher proportional expression of FoxP3 in top 1% of CD25^{high} cells, in which gating was determined by the corresponding isotype control (iso) or biological negative control (bio; CD25⁻). No significant difference was found in CD25^{high} cells between the two gating methods. Statistical significance in **(b,c)** was analysed by one-way ANOVA, followed by Dunn's multiple comparisons test (**** $p < 0.0001$, *** $p < 0.001$, ** $p < 0.01$, * $p < 0.05$).

Results

Freshly isolated canine CD4⁺CD25^{high} T cells are enriched for FoxP3. To test the hypothesis that freshly isolated canine CD4⁺CD25⁺ T cells have a regulatory phenotype, PBMCs of 11 healthy dogs were labelled with a mAb panel incorporating all markers of canine Tregs to date. When the CD25 gate was moved upwards to incorporate increasing CD25 expression per cell, from the highest 5% to the highest 0.2%, the proportion of FoxP3⁺ cells significantly increased from $36.89 \pm 2.79\%$ to $74.07 \pm 4.81\%$, suggesting that *ex vivo* CD4⁺CD25^{high} T cells were enriched for FoxP3 (Fig. 1a,b).

The top 1% of CD4⁺CD25⁺ T cells were selected for subsequent phenotypic characterisation, balancing the enrichment for FoxP3 ($61.59 \pm 4.76\%$) with the need to isolate sufficient numbers. The proportional expression of FoxP3 in CD4⁺CD25^{high} T cells was compared to CD4⁺CD25⁻ cells of the same dogs, the latter selected by gating the 20% of CD4⁺ T cells showing the lowest CD25 expression. FoxP3⁺ cells in the CD25^{high} fraction were gated in two ways, making a comparison with either the corresponding isotype control or the paired CD25⁻ population (a negative biological control). The two gating methods yielded similar results: CD25^{high} T cells had significantly greater FoxP3 expression than CD25⁻ T cells from the same dogs (Fig. 1c).




Figure 2. CD4⁺CD25^{high} T cells isolated *ex vivo* are suppressive *in vitro*. **(a)** Representative flow cytometric plots showing the proliferation of pre-labelled Tresp cells analysed in flow cytometry after a 96-hour incubation. Suppressor and responder cells were co-cultured at the ratio of 1:1. Tresp T cells of the four groups were gated following the same cascaded strategy: from live cells, to lymphocytes, to Tresp cells, followed by measurement *via* proportional proliferation. **(b)** Summary bar charts showing the proliferation of Tresp cells post 96-hour incubation (mean \pm SEM), measured by means of proportional proliferation, at both 1:1 and 1:2 suppressor:responder ratios (five independent experiments). Statistical significance was analysed by one-way ANOVA, followed by Holm-Sidak's multiple comparisons test. **(c)** Summary bar charts showing the percent suppression mediated by the suppressor population, normalised to parallel stimulated Tresp cells ((proliferating % of Tresp only – proliferating % of co-cultured Tresp)/(proliferating % of Tresp only) \times 100 (five independent experiments; mean \pm SEM). Statistical significance was determined by means of a paired *t* test (*****p* < 0.0001, ****p* < 0.001, ***p* < 0.01, **p* < 0.05).

Freshly isolated canine CD4⁺CD25^{high} T cells are suppressive *in vitro*. Freshly isolated CD4⁺CD25^{high} T cells suppressed conventional CD4⁺CD25⁻ T cell proliferation, as indicated by reduced cell divisions at a ratio of 1:1 or 1:2 in the presence of autologous monocytes (CD5⁺CD11b⁺) and ConA (Fig. 2). Our findings therefore confirmed the suppressive function of *ex vivo* canine CD4⁺CD25^{high} T cells. Given their regulatory phenotype and function, we then hypothesised that canine CD4⁺CD25^{high} T cells have a transcriptomic profile characteristic of Tregs.

Canine CD4⁺CD25^{high} T cells possess the transcriptomic signature of Tregs. We conducted RNA-seq on freshly isolated CD4⁺CD25^{high} and CD4⁺CD25⁻ T cells. PCA analysis revealed distinct expression signatures of the two cell types (Fig. 3a). A volcano plot confirmed the distinction and suggested a Treg-like phenotype of CD25^{high} T cells, which preferentially expressed nearly all of the known Treg-specific transcripts, such as *il2ra*, *foxp3*, *ikzf2*, *ctla4*, *il10*, *lgals3*, *tigit*, *nrp1*, *lag3*, *icam1* and *tnfrsf18*^{43,44} (Fig. 3b).

Ingenuity pathway analysis of canine CD4⁺CD25^{high} T cells. Pathway analysis further consolidated functional annotations of the CD25^{high} T cell expression signature in comparison to CD25⁻ T cells, which identified three pathways associated with development and function of Tregs to be activated, namely phospholipase C signalling, p38-mitogen activated protein kinase (MAPK) signalling and cell cycle regulation (Fig. 3c).

A Treg-specific expression signature is conserved in humans, mice and dogs. We compared Treg-specific transcriptomic signatures between species using similarity scores, which revealed a resemblance of canine CD4⁺CD25^{high} T cells to both human and murine Tregs for the top 100 most differentially expressed




Figure 4. A Treg-specific transcriptomic signature is conserved in humans, mice and dogs. **(a)** Similarity score analysis measured the resemblance between differentially expressed transcripts of canine CD4⁺CD25^{high} T cells with those of human and murine Tregs, on the basis of 772 consensus transcripts. Similarity score was calculated using the ranked top 100, 150, 200, 300, 400, 500 and 750 transcripts, respectively, with an accompanying p value. The dashed line indicates $p = 0.05$. **(b)** Venn diagram showing highly enriched transcripts (with more than two-fold preferential expression) consensus between canine CD4⁺CD25^{high} T cells and, human and murine Tregs. **(c)** Stacked bar charts showing the 31 consensus transcripts conserved in all three species, with corresponding FC values in log₂ format. Transcripts selected for RT-qPCR validation are highlighted in orange. **(d)** Scatter plots showing relative expression FC values of transcripts validated by RT-qPCR, plotted in log₂ format. The line indicates median value of the three or four sample replicates. **(e)** Stacked bar charts showing expression FC values of transcripts preferentially expressed by canine CD4⁺CD25^{high} T cells compatible between RNA-seq and RT-qPCR detection, plotted in log₂ format.

Apart from FoxP3 and other Treg signature molecules, we found that the canine CD4⁺CD25^{high} T cells expressed transcripts encoding transcription factors specific to pro-inflammatory T helper (Th) cells in greater abundance than CD4⁺CD25⁻ T cells. For instance, CD25^{high} T cells preferentially expressed *gata3* and *irf4* of Th2 cells^{51–53} and, *batf*, *ikzf3*, *ikzf4* and *rora* of Th17 cells^{54–57}. A trivial explanation of this phenomenon was enrichment of effector Th cells within the CD25^{high} T cells, which were not exclusively FoxP3⁺ and likely to be contaminated by Th cells. Healthy dogs are exposed to environmental antigens at mucosal surfaces on a continuous basis, with subsequent polarisation of a proportion of the local T cells and escape of these cells into the peripheral blood. An alternative explanation was that some of the peripheral Tregs themselves expressed Th-specific transcription factors, as has been previously documented^{25,58–62}. The CD4⁺CD25^{high} T cells also expressed a number of homing receptor transcripts at greater abundance than the CD4⁺CD25⁻ T cells. For instance, CD25^{high} T cells preferentially expressed Th2-associated chemokine receptor transcripts *ccr3*, *ccr4* and *ccr8*^{63–65}, in line with the

greater expression of Th2 transcription factor transcripts *gata3* and *irf4*. Other chemokine receptors enriched in canine CD25^{high} T cells are expressed by human and murine Tregs resident in various tissues and organs, i.e. CXCR6 and CCR3 in adipose tissue⁶⁶, CCR2, CCR5 and CXCR3 in pancreas⁶⁷, CCR4 in skin^{68,69} and, CCR2, CCR5 and CCR8 in muscle⁷⁰. In contrast, CD25^{high} T cells expressed three transcripts encoding naïve T cell homing molecules CD62L (L-selectin), CCR7 and IL7R^{71–74} in lower abundance. Trafficking of Tregs to peripheral lymphoid and non-lymphoid niches is critical to their functions in homeostasis, autoimmune disease and cancer in humans and mice, and expression of homing receptors may vary with developmental stage and target locations of Tregs^{68,70,75–80}. Single-cell RNA-seq would be required to distinguish whether these differential expression patterns were attributable to contaminant Th cells or to *bona fide* Tregs. Nevertheless, these data raise the intriguing possibility of ectopic expression of Th-specific transcripts by Tregs in dogs, as in other species: for instance, human Tregs isolated *ex vivo* from healthy donors express *gata3* and *ccr4* of Th2 cells²⁵, and murine Tregs incorporate *irf4* to suppress Th2 response⁵⁸.

Pathways associated with the development and function of canine Tregs were identified in our dataset. A cascade of signal transduction pathways is engaged upstream and downstream of FoxP3, dedicating Tregs to lineage-specific commitment^{81–88}. Phospholipase C signalling is a critical transduction pathway downstream of TCR activation in Tregs, and its defect causes profound autoimmune lesions in mice⁸⁹. The dominant mediator phospholipase C produces secondary messenger molecules 1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG)^{90–92}. IP₃ activates calcium flux, which then triggers the transcription factor nuclear factor of activated T cells (NFAT) to interact with FoxP3^{89,91}. DAG functions in a cascade upstream of p38-MAPK signalling, which regulates the cell cycle and is indispensable in the induction of anergy and maintenance of Treg suppressive function⁹³. The upregulation of phospholipase C, p38-MAPK and cell cycle regulation pathways in canine Tregs accords with these observations.

We interrogated expression signatures of Tregs across species, reasoning that similarity of transcripts would speak to their core function in Tregs. Canine Tregs resembled both human and murine Tregs, yielding 31 common differentially expressed transcripts. More than half of the 31 consensus transcripts encode Treg-specific molecules, indicative of interspecies conservation of Treg signature. Of the 12 transcripts not hitherto related to Tregs, *hip1* has potential immunoregulatory relevance. Hip1 is a serine hydrolase protein embedded in cell envelopes of *Mycobacterium tuberculosis*, which reside intracellularly in macrophages and dendritic cells (DCs) of the host, evading immune responses by impeding functions of these primary APCs using Hip1^{94–97}. First, *M. tuberculosis* deactivates Toll-like receptor 2 and MyD88-dependent pathways *via* Hip1, reducing activation and cytokine production of macrophages and DCs^{94,96}. Second, *M. tuberculosis* disrupts interactions between CD4⁺ T cells and APCs through GroEL2, a product of Hip1 hydrolysis^{95,97}. Therefore, Hip1 may be another mechanism by which Tregs negatively modulate APCs. Fam129a and Alpha actinin-4 encoded by *fam129a* and *actn4* inhibit cell apoptosis^{98,99}, and Cathepsin Z, encoded by *ctsz*, promotes angiogenesis and metastasis^{100,101}. These three proteins could potentially be blocked by specific mAb to attenuate the number and function of Tregs in the cancer microenvironment. The remaining eight transcripts are involved in T cell activation: protein products of *cadm1*, *frmd4b*, *lmna*, *anxa2*, *galm*, *pou2f2*, *csf1* and *ptprj* may directly or indirectly enhance TCR signalling or interaction of T cells with APCs^{102–109}. Single cell RNA-seq would be required to further explore the significance of these transcripts to Tregs, along with confirmation of differential expression of their protein products and their role in suppressive function, if any.

In conclusion, we have characterised the phenotype, function, and transcriptomic signature of canine Tregs. We have delineated a core set of 31 transcripts that show differential expression by the Tregs of three mammalian species, including humans. More than half of these transcripts have been previously associated with Tregs in mice and humans. However, 12 transcripts have hitherto not been associated with Tregs in any species, prompting further questions about their role in this cellular context. This comparative approach is a powerful tool in generating hypotheses that may yield fresh mechanistic insights or novel immunotherapeutic targets in this important, yet elusive, area of immunology.

Data Availability

Raw and processed canine RNA-seq data of this study have been deposited to Gene Expression Omnibus (GEO), accession number GSE132068.

References

- Ohkura, N., Kitagawa, Y. & Sakaguchi, S. Development and maintenance of regulatory T cells. *Immunity* **38**, 414–423, <https://doi.org/10.1016/j.immuni.2013.03.002> (2013).
- Sasada, T., Kimura, M., Yoshida, Y., Kanai, M. & Takabayashi, A. CD4⁺CD25⁺ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. *Cancer* **98**, 1089–1099, <https://doi.org/10.1002/cncr.11618> (2003).
- Curiel, T. J. *et al.* Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med* **10**, 942–949, <https://doi.org/10.1038/nm1093> (2004).
- Bennett, C. L. *et al.* The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nature genetics* **27**, 20–21, <https://doi.org/10.1038/83713> (2001).
- Shitara, K. & Nishikawa, H. Regulatory T cells: a potential target in cancer immunotherapy. *Ann N Y Acad Sci* **1417**, 104–115, <https://doi.org/10.1111/nyas.13625> (2018).
- Sharabi, A. *et al.* Regulatory T cells in the treatment of disease. *Nature reviews. Drug discovery*. <https://doi.org/10.1038/nrd.2018.148> (2018).
- Romano, M., Tung, S. L., Smyth, L. A. & Lombardi, G. Treg therapy in transplantation: a general overview. *Transplant international: official journal of the European Society for Organ Transplantation* **30**, 745–753, <https://doi.org/10.1111/tri.12909> (2017).
- Benoist, C. & Mathis, D. Treg cells, life history, and diversity. *Cold Spring Harb Perspect Biol* **4**, a007021, <https://doi.org/10.1101/cshperspect.a007021> (2012).

9. Sakaguchi, S., Vignali, D. A., Rudensky, A. Y., Nieu, R. E. & Waldmann, H. The plasticity and stability of regulatory T cells. *Nat Rev Immunol* **13**, 461–467, <https://doi.org/10.1038/nri3464> (2013).
10. Brockmann, L. *et al.* Molecular and functional heterogeneity of IL-10-producing CD4(+) T cells. *Nat Commun* **9**, 5457, <https://doi.org/10.1038/s41467-018-07581-4> (2018).
11. Gagliani, N. *et al.* Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. *Nat Med* **19**, 739–746, <https://doi.org/10.1038/nm.3179> (2013).
12. Zhang, S., Wu, M. & Wang, F. Immune regulation by CD8(+) Treg cells: novel possibilities for anticancer immunotherapy. *Cell Mol Immunol* **15**, 805–807, <https://doi.org/10.1038/cmi.2018.170> (2018).
13. Wang, R. F. CD8⁺ regulatory T cells, their suppressive mechanisms, and regulation in cancer. *Hum Immunol* **69**, 811–814, <https://doi.org/10.1016/j.humimm.2008.08.276> (2008).
14. Okamura, T. *et al.* CD4⁺CD25⁻LAG3⁺ regulatory T cells controlled by the transcription factor Egr-2. *Proc Natl Acad Sci USA* **106**, 13974–13979, <https://doi.org/10.1073/pnas.0906872106> (2009).
15. Okamura, T., Yamamoto, K. & Fujio, K. Early growth response gene 2-expressing CD4(+)LAG3(+) regulatory T cells: the therapeutic potential for treating autoimmune diseases. *Front Immunol* **9**, 340, <https://doi.org/10.3389/fimmu.2018.00340> (2018).
16. Li, X. *et al.* Generation of human regulatory gammadelta T cells by TCRgammadelta stimulation in the presence of TGF-beta and their involvement in the pathogenesis of systemic lupus erythematosus. *J Immunol* **186**, 6693–6700, <https://doi.org/10.4049/jimmunol.1002776> (2011).
17. Wesch, D., Peters, C. & Siegers, G. M. Human gamma delta T regulatory cells in cancer: fact or fiction? *Front Immunol* **5**, 598, <https://doi.org/10.3389/fimmu.2014.00598> (2014).
18. Krovi, S. H. & Gapin, L. Invariant natural killer T cell subsets—more than just developmental intermediates. *Front Immunol* **9**, 1393, <https://doi.org/10.3389/fimmu.2018.01393> (2018).
19. Lam, P. Y., Nissen, M. D. & Mattarollo, S. R. Invariant natural killer T cells in immune regulation of blood cancers: harnessing their potential in immunotherapies. *Front Immunol* **8**, 1355, <https://doi.org/10.3389/fimmu.2017.01355> (2017).
20. Itoh, M. *et al.* Thymus and autoimmunity: production of CD25⁺CD4⁺ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. *J Immunol* **162**, 5317–5326 (1999).
21. Sakaguchi, S., Miyara, M., Costantino, C. M. & Hafler, D. A. FOXP3⁺ regulatory T cells in the human immune system. *Nat Rev Immunol* **10**, 490–500, <https://doi.org/10.1038/nri2785> (2010).
22. Kitagawa, Y. *et al.* Guidance of regulatory T cell development by Satb1-dependent super-enhancer establishment. *Nature immunology* **18**, 173–183, <https://doi.org/10.1038/ni.3646> (2017).
23. Stephens, G. L., Andersson, J. & Shevach, E. M. Distinct subsets of FoxP3⁺ regulatory T cells participate in the control of immune responses. *The Journal of Immunology* **178**, 6901–6911, <https://doi.org/10.4049/jimmunol.178.11.6901> (2007).
24. Hansmann, L. *et al.* Dominant Th2 differentiation of human regulatory T cells upon loss of FOXP3 expression. *J Immunol* **188**, 1275–1282, <https://doi.org/10.4049/jimmunol.1102288> (2012).
25. Duhon, T., Duhon, R., Lanzavecchia, A., Sallusto, F. & Campbell, D. J. Functionally distinct subsets of human FOXP3⁺ Treg cells that phenotypically mirror effector Th cells. *Blood* **119**, 4430–4440, <https://doi.org/10.1182/blood-2011-11-392324> (2012).
26. Miyara, M. *et al.* Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3^{high} regulatory T cells in humans. *Proc Natl Acad Sci USA* **112**, 7225–7230, <https://doi.org/10.1073/pnas.1508224112> (2015).
27. Garden, O. A., Pinheiro, D. & Cunningham, F. All creatures great and small: regulatory T cells in mice, humans, dogs and other domestic animal species. *Int Immunopharmacol* **11**, 576–588, <https://doi.org/10.1016/j.intimp.2010.11.003> (2011).
28. Pinheiro, D. *et al.* Dissecting the regulatory microenvironment of a large animal model of non-Hodgkin lymphoma: evidence of a negative prognostic impact of FOXP3⁺ T cells in canine B cell lymphoma. *PLoS one* **9**, e105027, <https://doi.org/10.1371/journal.pone.0105027> (2014).
29. Richards, K. L. & Suter, S. E. Man's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma? *Immunological reviews* **263**, 173–191, <https://doi.org/10.1111/immr.12238> (2015).
30. Biller, B. J., Elmslie, R. E., Burnett, R. C., Avery, A. C. & Dow, S. W. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. *Vet Immunol Immunopathol* **116**, 69–78, <https://doi.org/10.1016/j.vetimm.2006.12.002> (2007).
31. Pinheiro, D. *et al.* Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog. *Immunology* **132**, 111–122, <https://doi.org/10.1111/j.1365-2567.2010.03346.x> (2011).
32. Abrams, V. K. *et al.* A novel monoclonal antibody specific for canine CD25 (P4A10): selection and evaluation of canine Tregs. *Vet Immunol Immunopathol* **135**, 257–265, <https://doi.org/10.1016/j.vetimm.2009.12.006> (2010).
33. Viguier, M. *et al.* Foxp3 expressing CD4⁺CD25^{high} regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. *The Journal of Immunology* **173**, 1444–1453, <https://doi.org/10.4049/jimmunol.173.2.1444> (2004).
34. Rodriguez-Perea, A. L., Arcia, E. D., Rueda, C. M. & Velilla, P. A. Phenotypic characterization of regulatory T cells in humans and rodents. *Clin Exp Immunol* **185**, 281–291, <https://doi.org/10.1111/cei.12804> (2016).
35. Nishioka, T., Shimizu, J., Iida, R., Yamazaki, S. & Sakaguchi, S. CD4⁺CD25⁺Foxp3⁺ T cells and CD4⁺CD25⁻Foxp3⁺ T cells in aged mice. *The Journal of Immunology* **176**, 6586–6593, <https://doi.org/10.4049/jimmunol.176.11.6586> (2006).
36. Knueppel, A. *et al.* Phenotypic and functional characterization of freshly isolated and expanded canine regulatory T cells. *Exp Anim* **60**, 471–479 (2011).
37. Archer, T. M. *et al.* In vivo effects of aspirin and cyclosporine on regulatory T cells and T-cell cytokine production in healthy dogs. *Vet Immunol Immunopathol* **197**, 63–68, <https://doi.org/10.1016/j.vetimm.2018.01.003> (2018).
38. Palatucci, A. T. *et al.* Circulating regulatory T cells (Treg), leptin and induction of proinflammatory activity in obese Labrador Retriever dogs. *Vet Immunol Immunopathol* **202**, 122–129, <https://doi.org/10.1016/j.vetimm.2018.07.004> (2018).
39. Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic acids research* **29**, e45 (2001).
40. Albert, M. H. *et al.* MiRNome and transcriptome aided pathway analysis in human regulatory T cells. *Genes and immunity* **15**, 303–312, <https://doi.org/10.1038/gene.2014.20> (2014).
41. Afgan, E. *et al.* The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. *Nucleic acids research* **46**, W537–W544, <https://doi.org/10.1093/nar/gky379> (2018).
42. Auray, G. *et al.* Characterization and transcriptomic analysis of porcine blood conventional and plasmacytoid dendritic cells reveals striking species-specific differences. *J Immunol* **197**, 4791–4806, <https://doi.org/10.4049/jimmunol.1600672> (2016).
43. Bhairavabhotla, R. *et al.* Transcriptome profiling of human Foxp3⁺ regulatory T cells. *Hum Immunol* **77**, 201–213, <https://doi.org/10.1016/j.humimm.2015.12.004> (2016).
44. Birzele, F. *et al.* Next-generation insights into regulatory T cells: expression profiling and FoxP3 occupancy in Human. *Nucleic acids research* **39**, 7946–7960, <https://doi.org/10.1093/nar/gkr444> (2011).
45. Bonnal, R. J. *et al.* De novo transcriptome profiling of highly purified human lymphocytes primary cells. *Sci Data* **2**, 150051, <https://doi.org/10.1038/sdata.2015.51> (2015).
46. Zemmour, D. *et al.* Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR. *Nature immunology* **19**, 291–301, <https://doi.org/10.1038/s41590-018-0051-0> (2018).
47. Zheng, C. *et al.* Landscape of infiltrating T Cells in liver cancer revealed by single-cell sequencing. *Cell* **169**, 1342–1356 e1316, <https://doi.org/10.1016/j.cell.2017.05.035> (2017).

48. Dong, S. *et al.* Multiparameter single-cell profiling of human CD4⁺FOXP3⁺ regulatory T-cell populations in homeostatic conditions and during graft-versus-host disease. *Blood* **122**, 1802–1812, <https://doi.org/10.1182/blood-2013-02-482539> (2013).
49. Schmidl, C. *et al.* The enhancer and promoter landscape of human regulatory and conventional T-cell subpopulations. *Blood* **123**, e68–78, <https://doi.org/10.1182/blood-2013-02-486944> (2014).
50. Ubaid, U. *et al.* Transcriptional repressor HIC1 contributes to suppressive function of human induced regulatory T cells. *Cell Rep* **22**, 2094–2106, <https://doi.org/10.1016/j.celrep.2018.01.070> (2018).
51. O'Garra, A. & Gabrysova, L. Transcription factors directing Th2 differentiation: Gata-3 plays a dominant role. *J Immunol* **196**, 4423–4425, <https://doi.org/10.4049/jimmunol.1600646> (2016).
52. Lohoff, M. *et al.* Dysregulated T helper cell differentiation in the absence of interferon regulatory factor 4. *Proc Natl Acad Sci USA* **99**, 11808–11812, <https://doi.org/10.1073/pnas.182425099> (2002).
53. Rengarajan, J. *et al.* Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. *The Journal of Experimental Medicine* **195**, 1003–1012, <https://doi.org/10.1084/jem.20011128> (2002).
54. Martinez, G. J. & Dong, C. BATF: bringing (in) another Th17-regulating factor. *J Mol Cell Biol* **1**, 66–68, <https://doi.org/10.1093/jmcb/mjp016> (2009).
55. Yang, X. O. *et al.* T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. *Immunity* **28**, 29–39, <https://doi.org/10.1016/j.immuni.2007.11.016> (2008).
56. van Hamburg, J. P. & Tas, S. W. Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis. *J Autoimmun* **87**, 69–81, <https://doi.org/10.1016/j.jaut.2017.12.006> (2018).
57. Liu, S. Q., Jiang, S., Li, C., Zhang, B. & Li, Q. J. miR-17-92 cluster targets phosphatase and tensin homology and Ikaros Family Zinc Finger 4 to promote Th17-mediated inflammation. *J Biol Chem* **289**, 12446–12456, <https://doi.org/10.1074/jbc.M114.550723> (2014).
58. Zheng, Y. *et al.* Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. *Nature* **458**, 351–356, <https://doi.org/10.1038/nature07674> (2009).
59. Ayyoub, M. *et al.* Human memory FOXP3⁺ Tregs secrete IL-17 *ex vivo* and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. *Proc Natl Acad Sci USA* **106**, 8635–8640, <https://doi.org/10.1073/pnas.0900621106> (2009).
60. Schmidl, C. *et al.* Epigenetic reprogramming of the RORC locus during *in vitro* expansion is a distinctive feature of human memory but not naive Treg. *European journal of immunology* **41**, 1491–1498, <https://doi.org/10.1002/eji.201041067> (2011).
61. Chaudhry, A. *et al.* CD4⁺ regulatory T cells control Th17 responses in a Stat3-dependent manner. *Science* **326**, 986–991, <https://doi.org/10.1126/science.1172702> (2009).
62. Koch, M. A. *et al.* The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. *Nature immunology* **10**, 595–602, <https://doi.org/10.1038/ni.1731> (2009).
63. Sallusto, F., Mackay, C. R. & Lanzavecchia, A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. *Science* **277** (1997).
64. Zhou, S. F. *et al.* Characterization of Th1- and Th2-associated chemokine receptor expression in spleens of patients with immune thrombocytopenia. *J Clin Immunol* **33**, 938–946, <https://doi.org/10.1007/s10875-013-9883-4> (2013).
65. D'Ambrosio, D. *et al.* Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. *J Immunol* **161**, 5111–5115 (1998).
66. Cipolletta, D. *et al.* PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. *Nature* **486**, 549–553, <https://doi.org/10.1038/nature11132> (2012).
67. Chen, Z., Herman, A. E., Matos, M., Mathis, D. & Benoist, C. Where CD4⁺CD25⁺ T reg cells impinge on autoimmune diabetes. *J Exp Med* **202**, 1387–1397, <https://doi.org/10.1084/jem.20051409> (2005).
68. Sather, B. D. *et al.* Altering the distribution of Foxp3(+) regulatory T cells results in tissue-specific inflammatory disease. *J Exp Med* **204**, 1335–1347, <https://doi.org/10.1084/jem.20070081> (2007).
69. Iellem, A., Colantonio, L. & D'Ambrosio, D. Skin-versus gut-skewed homing receptor expression and intrinsic CCR4 expression on human peripheral blood CD4⁺CD25⁺ suppressor T cells. *European journal of immunology* **33**, 1488–1496, <https://doi.org/10.1002/eji.200323658> (2003).
70. Burzyn, D. *et al.* A special population of regulatory T cells potentiates muscle repair. *Cell* **155**, 1282–1295, <https://doi.org/10.1016/j.cell.2013.10.054> (2013).
71. Ley, K. & Kansas, G. S. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. *Nat Rev Immunol* **4**, 325–335, <https://doi.org/10.1038/nri1351> (2004).
72. Masopust, D. & Schenkel, J. M. The integration of T cell migration, differentiation and function. *Nat Rev Immunol* **13**, 309–320, <https://doi.org/10.1038/nri3442> (2013).
73. Carrette, F. & Surh, C. D. IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis. *Semin Immunol* **24**, 209–217, <https://doi.org/10.1016/j.smim.2012.04.010> (2012).
74. Surh, C. D. & Sprent, J. Homeostasis of naive and memory T cells. *Immunity* **29**, 848–862, <https://doi.org/10.1016/j.immuni.2008.11.002> (2008).
75. Abadier, M. *et al.* Effector and regulatory T cells roll at high shear stress by inducible tether and sling formation. *Cell Rep* **21**, 3885–3899, <https://doi.org/10.1016/j.celrep.2017.11.099> (2017).
76. Campbell, D. J. Control of regulatory T cell migration, function, and homeostasis. *J Immunol* **195**, 2507–2513, <https://doi.org/10.4049/jimmunol.1500801> (2015).
77. Chow, Z., Banerjee, A. & Hickey, M. J. Controlling the fire—tissue-specific mechanisms of effector regulatory T-cell homing. *Immunol Cell Biol* **93**, 355–363, <https://doi.org/10.1038/icb.2014.117> (2015).
78. Ding, Y., Xu, J. & Bromberg, J. S. Regulatory T cell migration during an immune response. *Trends Immunol* **33**, 174–180, <https://doi.org/10.1016/j.it.2012.01.002> (2012).
79. Lim, H. W., Broxmeyer, H. E. & Kim, C. H. Regulation of trafficking receptor expression in human Forkhead Box P3⁺ regulatory T cells. *The Journal of Immunology* **177**, 840–851, <https://doi.org/10.4049/jimmunol.177.2.840> (2006).
80. Siewert, C. *et al.* Induction of organ-selective CD4⁺ regulatory T cell homing. *European journal of immunology* **37**, 978–989, <https://doi.org/10.1002/eji.200636575> (2007).
81. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. *Science* **299**, 1057–1061, <https://doi.org/10.1126/science.1079490> (2003).
82. Josefowicz, S. Z. & Rudensky, A. Control of regulatory T cell lineage commitment and maintenance. *Immunity* **30**, 616–625, <https://doi.org/10.1016/j.immuni.2009.04.009> (2009).
83. Zheng, Y. *et al.* Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. *Nature* **445**, 936–940, <https://doi.org/10.1038/nature05563> (2007).
84. Hill, J. A. *et al.* Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. *Immunity* **27**, 786–800, <https://doi.org/10.1016/j.immuni.2007.09.010> (2007).
85. Crellin, N. K., Garcia, R. V. & Levings, M. K. Altered activation of AKT is required for the suppressive function of human CD4⁺CD25⁺ T regulatory cells. *Blood* **109**, 2014–2022, <https://doi.org/10.1182/blood-2006-07-035279> (2007).
86. Sauer, S. *et al.* T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. *Proc Natl Acad Sci USA* **105**, 7797–7802, <https://doi.org/10.1073/pnas.0800928105> (2008).

87. Marson, A. *et al.* Foxp3 occupancy and regulation of key target genes during T-cell stimulation. *Nature* **445**, 931–935, <https://doi.org/10.1038/nature05478> (2007).
88. Lee, W. & Lee, G. R. Transcriptional regulation and development of regulatory T cells. *Exp Mol Med* **50**, e456, <https://doi.org/10.1038/emm.2017.313> (2018).
89. Fu, G. *et al.* Phospholipase C[gamma]1 is essential for T cell development, activation, and tolerance. *J Exp Med* **207**, 309–318, <https://doi.org/10.1084/jem.20090880> (2010).
90. Wells, A. D. *et al.* Regulation of T cell activation and tolerance by Phospholipase C-1-dependent integrin avidity modulation. *The Journal of Immunology* **170**, 4127–4133, <https://doi.org/10.4049/jimmunol.170.8.4127> (2003).
91. Putney, J. W. & Tomita, T. Phospholipase C signaling and calcium influx. *Adv Biol Regul* **52**, 152–164, <https://doi.org/10.1016/j.advenzreg.2011.09.005> (2012).
92. Kawakami, T. & Xiao, W. Phospholipase C-beta in immune cells. *Adv Biol Regul* **53**, 249–257, <https://doi.org/10.1016/j.jbior.2013.08.001> (2013).
93. Adler, H. S. & Steinbrink, K. MAP kinase p38 and its relation to T cell energy and suppressor function of regulatory T cells. *Cell Cycle* **7**, 169–170, <https://doi.org/10.4161/cc.7.2.5312> (2008).
94. Madan-Lala, R., Peixoto, K. V., Re, F. & Rengarajan, J. Mycobacterium tuberculosis Hip1 dampens macrophage proinflammatory responses by limiting toll-like receptor 2 activation. *Infect Immun* **79**, 4828–4838, <https://doi.org/10.1128/IAI.05574-11> (2011).
95. Georgieva, M., Sia, J. K., Bizzell, E., Madan-Lala, R. & Rengarajan, J. Mycobacterium tuberculosis GroEL2 modulates dendritic cell responses. *Infect Immun* **86**, <https://doi.org/10.1128/IAI.00387-17> (2018).
96. Madan-Lala, R. *et al.* Mycobacterium tuberculosis impairs dendritic cell functions through the serine hydrolase Hip1. *J Immunol* **192**, 4263–4272, <https://doi.org/10.4049/jimmunol.1303185> (2014).
97. Naffin-Olivos, J. L. *et al.* Mycobacterium tuberculosis Hip1 modulates macrophage responses through proteolysis of GroEL2. *PLoS Pathog* **10**, e1004132, <https://doi.org/10.1371/journal.ppat.1004132> (2014).
98. Chakraborty, S. *et al.* Alpha-actinin 4 potentiates myocyte enhancer factor-2 transcription activity by antagonizing histone deacetylase 7. *J Biol Chem* **281**, 35070–35080, <https://doi.org/10.1074/jbc.M602474200> (2006).
99. Ji, H. *et al.* AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis. *EMBO reports* **13**, 554–560, <https://doi.org/10.1038/embor.2012.53> (2012).
100. Bernhardt, A., Kuester, D., Roessner, A., Reinheckel, T. & Krueger, S. Cathepsin X-deficient gastric epithelial cells in co-culture with macrophages: characterization of cytokine response and migration capability after Helicobacter pylori infection. *J Biol Chem* **285**, 33691–33700, <https://doi.org/10.1074/jbc.M110.146183> (2010).
101. Sevenich, L. *et al.* Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. *Proc Natl Acad Sci USA* **107**, 2497–2502, <https://doi.org/10.1073/pnas.0907240107> (2010).
102. Nakahata, S. & Morishita, K. CADM1/TSLC1 is a novel cell surface marker for adult T-cell leukemia/lymphoma. *Journal of clinical and experimental hematopathology: JCEH* **52**, 17–22 (2012).
103. Gonzalez-Granado, J. M. *et al.* Nuclear envelope lamin-A couples actin dynamics with immunological synapse architecture and T cell activation. *Science signaling* **7**, ra37, <https://doi.org/10.1126/scisignal.2004872> (2014).
104. Marlin, R. *et al.* Sensing of cell stress by human gamma delta TCR-dependent recognition of annexin A2. *Proc Natl Acad Sci USA* **114**, 3163–3168, <https://doi.org/10.1073/pnas.1621052114> (2017).
105. Klarlund, J. K. *et al.* Signaling complexes of the FERM domain-containing protein GRSP1 bound to ARF exchange factor GRP1. *J Biol Chem* **276**, 40065–40070, <https://doi.org/10.1074/jbc.M105260200> (2001).
106. Pai, T., Chen, Q., Zhang, Y., Zolfaghari, R. & Ross, A. C. Galactomutarotase and other galactose-related genes are rapidly induced by retinoic acid in human myeloid cells. *Biochemistry* **46**, 15198–15207, <https://doi.org/10.1021/bi701891t> (2007).
107. Corcoran, L. *et al.* Oct2 and Obf1 as facilitators of B:T cell collaboration during a humoral immune response. *Front Immunol* **5**, 108, <https://doi.org/10.3389/fimmu.2014.00108> (2014).
108. Zhu, Y. *et al.* CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. *Cancer Res* **74**, 5057–5069, <https://doi.org/10.1158/0008-5472.CAN-13-3723> (2014).
109. Omerovic, J., Clague, M. J. & Prior, I. A. Phosphatome profiling reveals PTPN2, PTPRJ and PTEN as potent negative regulators of PKB/Akt activation in Ras-mutated cancer cells. *The Biochemical journal* **426**, 65–72, <https://doi.org/10.1042/bj20091413> (2010).

Acknowledgements

We are grateful to all the owners for kindly volunteering their dogs, and to the Clinical Investigation Centre of the Royal Veterinary College for collecting blood samples. We wish to thank the Oxford Genomics Centre at the Wellcome Centre for Human Genetics for performing RNA sequencing and initial data analysis. We also thank the Petplan Charitable Trust for funding this study. Additional funding resources were derived from intramural grants at the RVC and Barts Cancer Institute.

Author Contributions

Y.W. conducted the entire study and wrote the manuscript. Y.C. performed the volcano plot analysis and assisted with all the statistical analysis. A.J.S. and S.L.P. co-supervised Y.W. on project conduction and data interpretation. E.S. performed initial RNA-seq analysis and provided scripts for basic transcriptomic analysis. M.R.G. helped with suppression assay experiments. J.G. co-supervised Y.W. and co-funded the study. D.X. contributed expertise and intellectual input on all the transcriptomic data interpretation, and co-supervised Y.W. in the last year of the study. O.A.G. conceived and funded the study, recruited Y.W., served as the principal supervisor, and edited the manuscript. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-019-50065-8>.

Competing Interests: The authors declare no competing interests.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2019